Grape King Bio Ltd (TPE:1707)

Market Cap	19.18B
Revenue (ttm)	10.40B
Net Income (ttm)	1.22B
Shares Out	148.14M
EPS (ttm)	8.19
PE Ratio	15.81
Forward PE	n/a
Dividend	6.90 (5.37%)
Ex-Dividend Date	Jan 8, 2026

Volume	32,244
Average Volume	106,060
Open	129.50
Previous Close	129.50
Day's Range	129.00 - 129.50
52-Week Range	119.50 - 158.00
Beta	0.41
RSI	60.42
Earnings Date	Nov 11, 2025

About Grape King Bio

Grape King Bio Ltd, together with its subsidiaries, produces and sells pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy food in Taiwan, China, and internationally. It operates through Multi-Level Marketing; Distributors; Original Design Manufacturer/Original Equipment Manufacturer; and Sales Channel segments. The company offers Chinese herbal medicines, probiotics, energy drinks, and health food supplements for gastrointestinal health, immunity regulation, female beauty, and health care. It also provides functio...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1969
• Employees: 501
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 1707

Financial Performance

In 2024, Grape King Bio's revenue was 11.16 billion, an increase of 4.93% compared to the previous year's 10.64 billion. Earnings were 1.45 billion, a decrease of -0.30%.